HBW Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief: Delaney clause

This article was originally published in The Rose Sheet

Executive Summary

Delaney clause: Senate Labor and Human Resources Committee "recognizes the importance" of Delaney clause reform, according to the committee report on the Senate FDA reform bill (S 1477), filed June 20. "Every recent FDA commissioner has supported reevaluation and revision of the Delaney clause to reflect more recent scientific and technical advances," the report states. Furthermore, the report notes, both FDA and EPA use quantitative risk assessment to regulate carcinogenic substances and have adopted a negligible cancer-risk standard rather than a zero-risk standard. Sen. Judd Gregg (R-N.H.) introduced an amendment to S 1477 reforming Delaney clause during mark-up of the bill by the committee, but withdrew it due to inadequate time to properly consider the matter...
Advertisement
Advertisement
UsernamePublicRestriction

Register

RS002955

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel